Amgen Makes Repatha Available Through AmgenNow, a Direct-to-Patient Program

Amgen announced in October 2025 the launch of AmgenNow, a direct-to-patient program making evolocumab (Repatha) available at $239 per month — approximately 60% below the US list price, which Amgen claims is the lowest price available among G-7 countries. The program targets patients without insurance, those on high-deductible health plans, Medicare and Medicaid enrollees, and anyone preferring to pay out of pocket.

The announcement coincided with publication of the VESALIUS-CV trial results, the first large Phase 3 trial of a PCSK9 inhibitor in a primary prevention population — patients without prior myocardial infarction or stroke. That trial demonstrated significant reduction in major adverse cardiovascular events, extending evolocumab’s evidence base beyond secondary prevention into primary prevention of cardiovascular disease.

AmgenNow circumvents the traditional pharmacy benefit manager system. Patients enrolled in the program face no step therapy requirements and no prior authorization — the access barriers that have historically prevented eligible patients from filling PCSK9 inhibitor prescriptions. For the substantial fraction of commercially insured patients who never fill a PCSK9 inhibitor prescription due to insurance friction, a $239/month cash-pay option represents a meaningful alternative.

The pricing claims are specific and verifiable; the MACE reduction claims align with published trial data. The source is manufacturer promotional material — inherently framed to support product access — and independent verification of the comparative pricing claim (lowest in G-7) is not provided. The evidence strength reflects the reliable factual content of pricing and program terms, discounted for promotional framing.

We rate the evidence moderate. This Amgen press release announcing a direct-to-patient Repatha program at $239/month establishes a new access pathway for PCSK9 inhibitor therapy that bypasses the insurance prior authorization system — practically significant for the fraction of eligible patients currently unable to access treatment.